Osteotech — Merger or Acquisition (August 2010)
53 slides from Osteotech's merger presentation, Aug 17, 2010
Slide 1: Employee Communication August 17, 2010
Employee Communication August 17, 2010
Slide 2: Neighbors Helping Neighbors Food Drive
industrial way corridor neighbors helping neighbors FOOD DRIVE
Slide 3: From Tissue Processor to Biologics Innovator
From Tissue Processor to Biologics Innovator 1986 1991 2000 2005 2007 2009 2010 2011
Slide 4: Traditional Allograft Bone and Soft Tissue
traditional allograft BONE AND SOFT
Slide 5: Grafton Demineralized Bone Matrix (DBM)
grafton demineralized Bone Matrix (DBM) The Gold Standard in DBM
Slide 6: Graftech Structural Allografts
GRAFTECH STRUCTURAL ALLOGRAFTS
Slide 7: Exclusive Technology
Exausive Technology OF WhosteqtecH: 15 Months Post Op PROCEDURE “Dod
Slide 8: Exssive Techrology
Exssive Techrology ar OSTEOTECH"
Slide 9: Exausive Toctrology OF
Exausive Toctrology OF OSTEOTECH:* ili
Slide 10: MagniFuse Bone Graft
MagniPuse a MagniFuse’ BONE GRAFT MagniPuse: 3 ge 4 Mosrearec. > MagntPuse
Slide 11: Facet
FACET
Slide 12: ar OSTEOTECH"
ar OSTEOTECH"
Slide 13: Grafton in Spine
iosrea7EcH: » GRAFTON?’ in Spine gration 4 ns
Slide 14: Grafton Matrix — Posterior Lumbar
GRAFTON ® Matrix — Posterior Lumbar 1 Year Post Op
Slide 15: Grafton Matrix Strips — Spinal Deformity
GRAFTON ® Matrix Strips — Spinal Deformity
Slide 16: Grafton A-Flex — Acetabular Revision
GRAFTON ® A-Flex — Acetabular Revision Immediate Post Op 6 Months Post Op
Slide 17: Grafton Flex
ar OSTEOTECH" GRAFTON*® Flex
Slide 18: Grafton Gel — Percutaneous Injection
GRAFTON ® Gel — Percutaneous Injection
Slide 19: Exclusive Technology
Exasive Technology OF Whosteqrecr:
Slide 20: Plexur P Wedge
Plexur P ® Wedge Pre Op 8 Weeks Resumed Normal Activity
Slide 21: Plexur P Block
Plexur P ® Block Pre Op 3 Months Resumed Normal Activity
Slide 22: Plexur P Cylinder
Plexur P ® Cylinder Pre Op 3 Months Resumed Normal Activity
Slide 23: Time — Rabbit, Months — Rabbit
Time 0 — Rabbit 6 Months — Rabbit
Slide 24: Exclusive Technology
Excuse Technology OF Whosteqtecr PROCEDURE "Dod
Slide 25: Plexur M — Shatzker VI
Plexur M ® — Shatzker VI Pre Op Immediate Post Op 10 Months Post Op
Slide 26: Plexur M — Proximal Tibial Tumor
Plexur M ® — Proximal Tibial Tumor 44 Weeks Post Op 21 Weeks Post Op 7 Weeks Post Op Immediate Post Op
Slide 27: Injectable Non-weight Bearing Polyurethane Platform
Injectable Non-weight bearing Polyurethane platformPart A: Lysine triisocyanate-polyethylene glycol (LTI-PEG)Part B: Hardener (Polyol + catalyst) Setting time: 15 minutes Bone In situ Bone/polymer foam Setting time: 15 minutes Handling time: 3-5 minutes In situ Bone/polymer foam
Slide 28: MagniFuse
;OTECHE* Magnituse- aoe ea MagniFuse it f=2) . 4 ‘ BONE GRAFT \g ahr ¥ > MagniPuse wie MagniPuse Ps A &
Slide 29: Growth Factors in Natural Human Collagen
Growth Factors Full Array of Growth Factors Embedded in Natural Human Collagen • BMP 2,4,6,7 • TGF-? • PDGF • IGF Nanotechnology
Slide 30: MagniFuse Cervical & Thoracic
MagniFuse ® Cervical & Thoracic
Slide 31: MagniFuse PL: Rapid and Solid Bone Formation
MagniFuse ® PL 3 Months Post Op 6 Months Post Op Rapid and Solid Bone Formation
Slide 32: Rapid and Solid Bone Formation
Immediate Post Op 3 Months Post Op 6 Months Post Op Rapid and Solid Bone Formation
Slide 33: 6-Months Post Op (3-Dimensional CT Reconstruction)
6-Months Post Op (3-Dimensional CT Reconstruction)
Slide 34: MagniFuse
Whosteo7ecH: << MagniFuse
Slide 35: Se
Se
Slide 36: ar OSTEOTECH"
ar OSTEOTECH"
Slide 37: Microstructure 250x 1,000x 10,000x
Microstructure 250x 1,000x 10,000x
Slide 38: HCT Human Collagen Technology and Product Portfolio
HCT™ Human Collagen Technology MagniFuse ® Bone Graft FacetLinx™ Fusion Technology Plexur ® Innovative Grafting Grafton ® Demineralized Bone Matrix Xpanse ® Bone Insert Exhibit F:
Slide 39: Medtronic: Innovating for Life Town Hall Meeting
Medtronic: Innovating for Life Town Hall Meeting August 17, 2010 1 | MDT Confidential
Slide 40: The Early Years
The Early Years
Slide 41: The Place to Be ... A Rich History of Leadership
The Place to Be ... A Rich History of Leadership 50 ~50 21,000+ Diseases Treated Years of the Patents Awarded with Medtronic Medtronic Mission Products 7M 150,000+ $11B Patients Benefit fit Returned to from Medtronic Products Shareholders Products in Last 5 Years Annually
Slide 42: Innovation Has Driven Growth and Success
Innovation Has Driven Growth and Success Driven FY01 FY10 CRDM CardioVascular cular $ Billions lllioi nss 15.8 16 14.6 Physio Control 13.5 12.3 12 11.3 10.1 Spinal 9.1 8 7.7 6.4 5.6 Neuromodulation 4 Diabetes 0 FY01 FY02 FY03 FY04 FY05 FY06 FY07 FY08 FY09 FY10 Surgical Tech
Slide 43: Global Diversification has Driven Performance
Global Diversification has Driven Performance Europe & FY01 Central Asia Japan International Revenue Int’l Greater China % of Total Revenue 8 40% $ Billions Other Asia 6.5 6 5.6 5.2 4.4 Canada 4 3.7 30% 3.3 2.9 Middle East 2.3 1.9 1.9 & Africa 2 Latin America 0 20% FY01 FY02 FY03 FY04 FY05 FY06 FY07
Slide 44: Leading Positions in Chronic Disease Markets
Leading Positions in Chronic Disease Markets Chronic Disease Epidemic: Focus Positions Us for Growth Large, Growing and Costly 60% of deaths worldwide from chronic disease 17% growth in chronic disease deaths by 2015 of healthcare spending 75% on chronic disease
Slide 45: Integrating Technology to Deliver Innovation
Integrating Technology to Deliver Innovation LIFE SCIENCES Targeted Drug Delivery Materials ENGINEERING SCIENCES Power Sources Closed-Loop Systems Miniaturization INFORMATION Connected Care Imaging TECHNOLOGY Navigation
Slide 46: We Share a Patient-Centric Mission
We Share a Patient-Centric Mission “We believe our first responsibility is to use technology to enhance the gift of life; to develop therapy-driven products that alleviate pain and promote biological healing and restore function.”
Slide 47: Together, We Will Be Better Positioned To
Together, We Will Be Better Positioned To: Drive awareness and demand for Biologics Offer distinctive product portfolio and pipeline Create opportunities to develop breakthrough next-generation products Expand across treatment areas Accelerate growth internationally With our shared expertise, innova
Slide 48: Medtronic Therapy Portfolio
Medtronic Therapy Portfolio Growth Factors DBMs Synthetics Grafting INFUSE ® PROGENIX ® MASTERGRAFT ® Bone Structural Specialty Traditional CAPSTONE ® Cortical Facet Dowel Allograft Bone Chips Allograft CORNERSTONE ® Durepair ® PRECISION ®
Slide 49: Therapy Portfolio with Osteotech
Therapy Portfolio Osteotech Growth Factors DBMs Synthetics Grafting INFUSE ® GRAFTON ® MASTERGRAFT ® MAGNIFUSE ® PLEXUR ® Bone PROGENIX ® Structural Specialty Traditional CAPSTONE ® BioGenesis ® Allograft Bone Chips Allograft CORNERSTONE ® Cortical Facet Dowel Trad’l Allograft Graftech ® Durepair ®
Slide 50: Medtronic Biologics & Regenerative Therapies
Medtronic Biologics & Regenerative Therapies Distinctive Capabilities Global Revenue $ Millions World-class Biologics talent +37% 871 806 833 Gold-standard 701 commercial capabilities 571 Drug/device combo 413 product development 257 expertise 95 Industry-leading clinical and economic evidence FY03
Slide 51: Upside Remains in rhBMP-2 Franchise
Upside Remains in rhBMP-2 Franchise, and We Are Investing to Unlock New Applications Dental/CMF Current indications Sinus Aug. / Alveolar Cleft Ext. Sockets Ongoing studies New/projected studies Ridge Augmentation Multi-level ACDF 8 anticipated IDEs Cervical (ACDF) focus on the most Adult Deformity
Slide 52: Our Vision: Global Leader in Musculoskeletal Biologics
Our Vision: Global Leader in Musculoskeletal Biologics & Regenerative Therapies Broader Biologics s Stem cell therapy y rhGDF-5 Pain therapies Technologies Disc repair Diagnostics $1B Foundation New Bone grafting Opportunities Spine Orthopedics U.S. Dental Global Next Generation Products
Slide 53: Moving Forward: Guiding Principles for Integration
Moving Forward Guiding Principles to ensure seamless integration: 3 Maintain business momentum during the integration period 3 Understand and respect both cultures and how we operate 3 Never compromise quality or delivery of customer supply 3 Provide employees with frequent, direct and open communic